Literature DB >> 15210578

Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation.

Sheldon M Joseph1, Matthew A Pifer, Ronald J Przybylski, George R Dubyak.   

Abstract

1 Transient accumulation of extracellular ATP reflects both release of ATP from intracellular stores and altered rates of ATP metabolism by ecto-enzymes. Ecto-nucleoside triphosphate diphosphohydrolases (eNTPDases) and ecto-nucleotide pyrophosphatases (eNPPs) degrade ATP, while ecto-nucleotide diphosphokinases (eNDPKs) synthesize ATP from ambient ADP. 2 Although the methylene ATP analogs betagamma-meATP and alphabeta-meATP are widely used as metabolically stable tools for the analysis of purinergic signaling, their specific effects on eNTPDase, eNPP, and eNDPK activities have not been defined. This study compared the actions of these analogs on extracellular ATP metabolism by human 1321N1 astrocytes, rat PC12 pheochomocytoma cells, and rat C6 glioma cells. 3 Both analogs significantly reduced clearance of extracellular ATP by 1321N1 cells that express both eNTPDases and eNPPs, as well as by C6 cells that exclusively express eNPPs. In contrast, both analogs were much less efficacious in inhibiting ATP clearance by PC12 cells that predominantly express eNTPDases. Betagamma-meATP, but not alphabeta-meATP, was effectively hydrolyzed by the 1321N1 and C6 cells; PC12 cells did not significantly degrade this analog. 4 Alphabeta-meATP, but not betagamma-meATP, acted as a substrate for purified yeast NDPK to generate ATP via trans-phosphorylation of ADP. alphabeta-meATP also acted as substrate for the eNDPK activities expressed by 1321N1, PC12, and C6 cells and thereby induced extracellular ATP accumulation in the presence of ambient or exogenously added ADP. 5 These results indicate that methylene ATP analogs exert complex and cell-specific effects on extracellular ATP metabolism that can significantly modify interpretation of studies that use these reagents as probes of purinergic signal transduction in intact tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210578      PMCID: PMC1575113          DOI: 10.1038/sj.bjp.0705865

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes.

Authors:  Sheldon M Joseph; Marisa R Buchakjian; George R Dubyak
Journal:  J Biol Chem       Date:  2003-04-08       Impact factor: 5.157

2.  Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists.

Authors:  E R Lazarowski; L Homolya; R C Boucher; T K Harden
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase.

Authors:  B E Crack; C E Pollard; M W Beukers; S M Roberts; S F Hunt; A H Ingall; K C McKechnie; A P IJzerman; P Leff
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

4.  Use of firefly luciferase for ATP measurement: other nucleotides enhance turnover.

Authors:  S R Ford; K H Chenault; L S Bunton; G J Hampton; J McCarthy; M S Hall; S J Pangburn; L M Buck; F R Leach
Journal:  J Biolumin Chemilumin       Date:  1996 May-Jun

5.  Synthesis and properties of 8-azido-1, N6-etheno adenosine triphosphate--a fluorescent and photosensitive ATP analog.

Authors:  H J Schäfer; P Scheurich; G Rathgeber; K Dose
Journal:  Nucleic Acids Res       Date:  1978-04       Impact factor: 16.971

6.  Inhibition of ecto-ATPase by the P2 purinoceptor agonists, ATPgammaS, alpha,beta-methylene-ATP, and AMP-PNP, in endothelial cells.

Authors:  B C Chen; W W Lin
Journal:  Biochem Biophys Res Commun       Date:  1997-04-17       Impact factor: 3.575

7.  Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages.

Authors:  B C Chen; C M Lee; W W Lin
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

8.  Release and interconversion of P2 receptor agonists by human osteoblast-like cells.

Authors:  K A Buckley; S L Golding; J M Rice; J P Dillon; J A Gallagher
Journal:  FASEB J       Date:  2003-08       Impact factor: 5.191

9.  Hydrolysis of P2-purinoceptor agonists by a purified ectonucleotidase from the bovine aorta, the ATP-diphosphohydrolase.

Authors:  M Picher; J Sévigny; P D'Orléans-Juste; A R Beaudoin
Journal:  Biochem Pharmacol       Date:  1996-06-14       Impact factor: 5.858

10.  ATP analogues with modified phosphate chains and their selectivity for rat P2X2 and P2X2/3 receptors.

Authors:  Valeria Spelta; Abdelaziz Mekhalfia; Dominik Rejman; Mark Thompson; G Michael Blackburn; R Alan North
Journal:  Br J Pharmacol       Date:  2003-10-27       Impact factor: 8.739

View more
  27 in total

1.  Physiological regulation of ATP release at the apical surface of human airway epithelia.

Authors:  Seiko F Okada; Robert A Nicholas; Silvia M Kreda; Eduardo R Lazarowski; Richard C Boucher
Journal:  J Biol Chem       Date:  2006-06-05       Impact factor: 5.157

2.  2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.

Authors:  Shay Eliahu; Alba Martín-Gil; María Jesús Perez de Lara; Jesús Pintor; Jean Camden; Gary A Weisman; Joanna Lecka; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 3.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle.

Authors:  Ricardo Villa-Bellosta; Xiaonan Wang; José Luis Millán; George R Dubyak; W Charles O'Neill
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-13       Impact factor: 4.733

5.  Salivary extracellular vesicles can modulate purinergic signalling in oral tissues by combined ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase activities.

Authors:  Débora A González; Martín M Barbieri van Haaster; Emmanuel Quinteros Villarruel; Claude Hattab; Mariano A Ostuni; Betina Orman
Journal:  Mol Cell Biochem       Date:  2019-09-17       Impact factor: 3.396

6.  NPP1 is responsible for potent extracellular ATP hydrolysis as NTPDase1 in primary cultured murine microglia.

Authors:  Hye Min Lim; Woon Heo; Jung Woo Han; Min Goo Lee; Joo Young Kim
Journal:  Purinergic Signal       Date:  2018-03-07       Impact factor: 3.765

7.  Thrombin-promoted release of UDP-glucose from human astrocytoma cells.

Authors:  S M Kreda; L Seminario-Vidal; C van Heusden; E R Lazarowski
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

8.  Endoplasmic reticulum/golgi nucleotide sugar transporters contribute to the cellular release of UDP-sugar signaling molecules.

Authors:  Juliana I Sesma; Charles R Esther; Silvia M Kreda; Lisa Jones; Wanda O'Neal; Shoko Nishihara; Robert A Nicholas; Eduardo R Lazarowski
Journal:  J Biol Chem       Date:  2009-03-10       Impact factor: 5.157

9.  Quantification of extracellular UDP-galactose.

Authors:  Eduardo R Lazarowski
Journal:  Anal Biochem       Date:  2009-08-21       Impact factor: 3.365

10.  Identification of hydrolytically stable and selective P2Y(1) receptor agonists.

Authors:  Shay E Eliahu; Jean Camden; Joanna Lecka; Gary A Weisman; Jean Sévigny; Sylvie Gélinas; Bilha Fischer
Journal:  Eur J Med Chem       Date:  2008-07-22       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.